2023-509915-10-00招募中1 期
A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Hepatic Function
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 8
- 试验地点
- 2
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
EU GSK Clinical Trails Call Center
Scientific
Glaxosmithkline Research & Development Limited
研究点 (2)
Loading locations...
相似试验
招募中
2 期
Combination treatment of Belantamab Mafodotin and Venetoclax in treatment of relapsed and refractory t(11;14) Multiple Myeloma (Phase I/IIa) _ The BELI(E)VE-TrialMultiple Myeloma2024-511794-30-00University Medical Center Hamburg-Eppendorf1
招募中
1 期
A Phase I Study of Belantamab Mafodotin in Multiple Myeloma Participants with Normal and Impaired Renal Function2023-506063-34-00Glaxosmithkline Research & Development Limited9
进行中（未招募）
1 期
Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosisEUCTR2020-004001-32-GREuropean Myeloma Network – EM36
进行中（未招募）
1 期
Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosisrelapsed or refractory AL amyloidosisMedDRA version: 20.0Level: PTClassification code 10002022Term: AmyloidosisSystem Organ Class: 10021428 - Immune system disordersEUCTR2020-004001-32-FREuropean Myeloma Network – EM36
进行中（未招募）
1 期
Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosisRelapsed or refractory AL amyloidosis.MedDRA version: 20.0Level: PTClassification code 10002022Term: AmyloidosisSystem Organ Class: 10021428 - Immune system disordersEUCTR2020-004001-32-ITSTICHTING EUROPEAN MYELOMA NETWORK36